Proposals of the Shareholders’ Nomination Board of Detection Technology to the Annual General Meeting 2026

Detection Technology’s Shareholders’ Nomination Board proposes a six-member Board for the 2026 AGM with Marion Björkstén, Amy Chen, Richard Ingram, Henrik Roos, Jyrki Vainionpää and Antti Vasara standing for re-election and recommends Antti Vasara as Chair; all candidates are reported independent of the company except for ties between two members and A. Ahlström Oy (largest shareholder group). The Nomination Board proposes keeping annual fixed fees unchanged (Chair EUR 69,000; Vice Chair EUR 51,000; other members EUR 39,000), meeting fees (home country Chair EUR 1,000/others EUR 500; abroad Chair EUR 1,500/others EUR 1,000), committee meeting fees EUR 500, and allows directors to receive roughly 40% of annual cash remuneration in shares (VWAP over the month after the Q1 2026 report); the AGM is planned for 26 March 2026.

Analysis

Market structure: The Nomination Board’s unanimous re-election and stable fee proposal imply continuity rather than disruption — winners are incumbent shareholders (Ahlstrom group) and management stability that preserves execution risk; losers: none obvious. The 40% share-option on board fees creates incremental demand of ~€110k in shares annually (total fixed fees €276k x 40%), a negligible but positive micro buy signal likely <1% of free float for a typical small-cap, so pricing power and competitive positioning are unchanged in the near term (0–6 months).

Risk assessment: Tail risks include related-party influence from A. Ahlström Oy (two board linkages) that could suppress minority liquidity or lead to non-market transactions, regulatory risk in medical-device approvals, and China/India supply-chain disruptions. Immediate (days) effect: neutral; short-term (weeks/months): small positive around AGM (26 Mar 2026) and Q1 report windows; long-term (quarters/years): outcome depends on strategic alignment with Ahlstrom (support vs. over-control). Key hidden dependency: potential reliance on Ahlstrom for large orders or capital.

Trade implications: Direct: establish a modest 1–3% long in Detection Technology (DETEC: Nasdaq First North) ahead of AGM, target +30% in 6–12 months, stop-loss -15%. Pair trade: long DETEC vs short Varex Imaging (VREX) 0.5–1% notional to capture superior niche execution in subsystems. Options: collar DETEC position using 3‑month 10% OTM puts and selling 30% OTM calls to fund hedges around the post-Q1 VWAP issuance window.

Contrarian angles: Consensus will treat this as “no news”; that underestimates the signaling effect of share-paid fees aligning directors (~€110k demand) and the stabilizing role of a supportive anchor shareholder — possible underpriced governance stability. Conversely, if Ahlström consolidates >30% ownership or pushes strategic sales, institutional buyers may balk; monitor any related-party deal disclosures within 90 days post-AGM.

Key Decisions for Investors

• Initiate a 1–3% long position in Detection Technology (DETEC, Nasdaq First North) before the AGM on 26 Mar 2026; set a 6–12 month target of +30% and a hard stop-loss at -15% to limit small-cap volatility risk.
• Implement a relative-value pair trade: long DETEC (1%) vs short Varex Imaging (VREX, 0.5–1%) to isolate idiosyncratic governance/execution upside; rebalance if DETEC outperforms by +20% or underperforms by -10%.
• Hedge equity exposure via a collar for a 100% position size: buy 3-month puts 10% OTM and sell 3-month calls 30% OTM around the post-Q1 VWAP window (one-month after Q1 interim release) to monetize time value while protecting downside.
• Cap exposure if Ahlström-related disclosures show >30% ownership or any related-party transactions within 90 days post-AGM; reduce position to <0.5% or exit if such governance concentration is confirmed.
• Monitor three catalysts on a 30–90 day cadence: (1) Notice/packet for AGM (voting/language on related-party), (2) Q1 interim report release date (start of VWAP share-compensation window), and (3) any major product contract wins or regulatory approvals — add to position on positive proofs of commercial traction.